BriaCell Therapeutics Prices 1.45M Shares at $3.25, Raises $4.7M
BCTX•BriaCell Therapeutics priced a best-efforts offering of 1,449,300 common shares at $3.25 per share, raising approximately $4.7 million in gross proceeds. The offering, expected to close June 2, 2026, will fund working capital, general corporate purposes and business advancement.
1. Offering Structure
BriaCell Therapeutics launched a best-efforts offering of 1,449,300 common shares at an offering price of $3.25 each, resulting in gross proceeds of about $4.7 million before fees and expenses. The transaction is set to close on June 2, 2026, pending customary closing conditions.
2. Use of Proceeds
Net proceeds from the offering will be dedicated to working capital requirements, general corporate purposes and advancement of business objectives, supporting the company's clinical-stage immunotherapy programs.
3. Placement Agent and Regulatory Exemptions
ThinkEquity is acting as sole placement agent, and the offering relies on the Section 602.1 exemption under the TSX Company Manual for interlisted issuers on recognized exchanges such as Nasdaq.
